

Supplemental Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the Substitute Form PTO-1449 attached hereto as **Exhibit A**. Items 1-4 are either U.S. Patents or U.S. Patent Application Publications. As permitted by 37 C.F.R. 1.98(a)(2)(ii), no copies of items 1-4 are included herewith. Copies of items 5-29 are attached hereto as **Exhibits 1-25**, respectively.

1. U.S. Patent No. 7,345,153 issued March 18, 2008 to Litwin, Virginia M. et al.;
2. U.S. Patent Application Publication No. 2005-0131042 A1 published June 16, 2005 to Flentge, C.A.;
3. U.S. Patent Application Publication No. 2002-0177603 A1 published November 28, 2002 to Johnson, B.L. et al.;
4. U.S. Patent Application Publication No. 2006-0154857 A1, published July 13, 2006 to Redfield et al.;
5. Max, E. "Immunoglobulins: Molecular Genetics" in Fundamental Immunology, 6th edition. W.E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, 2008 pp. 192-236 (**Exhibit 1**);
6. Sanders et al. (2002) "The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120," Journal of Virology, pp. 7293-7305 (**Exhibit 2**);
7. Schroeder et al. (2008) "Immunoglobulins: Structure and Function," Fundamental Immunology, 6th Edition, Chapter 4, pp. 125-151 (**Exhibit 3**);
8. Nelson et al. "Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe,

Australia, and North America: 24-Week results," 14th Annual Conference on Retroviruses and Opportunistic Infections. 28 Feb 2007. Abstract #104aLB. Downloaded 3 Aug 2008 by Examiner

<<http://www.retroconference.org/2007/Abstracts/30636.htm>>
(Exhibit 4);

9. July 9, 2008 Office Action issued in connection with U.S. Serial No. 11/258,963 (Exhibit 5);
10. July 1, 2008 Office Action issued in connection with U.S. Serial No. 11/581,944 (Exhibit 6);
11. January 9, 2008 Final Office Action issued in connection with U.S. Serial No. 11/258,963 (Exhibit 7);
12. May 29, 2008 Office Action issued in connection with U.S. Serial No. 11/259,540 (Exhibit 8);
13. November 19, 2007 Final Office Action issued in connection with U.S. Serial No. 09/904,356 (Exhibit 9);
14. April 9, 2008 Office Action issued in connection with U.S. Serial No. 11/451,707 (Exhibit 10);
15. November 2, 2007 Office Action issued in connection with U.S. Serial No. 11/805,573 (Exhibit 11);
16. September 21, 2007 Notice of Allowance and Fee(s) Due, including a Notice of Allowability, issued in connection with U.S. Serial No. 11/544,346, now U.S. Patent No. 7,345,153 (Exhibit 12);
17. October 4, 2007 Office Action issued in connection with U.S. Serial No. 11/175,815 (Exhibit 13);
18. November 16, 2007 Office Action issued in connection with U.S. Serial No. 09/460,216 (Exhibit 14);
19. November 12, 2007 Final Office Action issued in connection with U.S. Serial No. 11/400,497 (Exhibit 15);
20. April 3, 2008 Office Action issued in connection with U.S. Serial No. 11/520,556 (Exhibit 16);

21. January 9, 2008 Office Action issued in connection with U.S. Serial No. 11/259,540 (Exhibit 17);
22. May 22, 2008 Office Action issued in connection with U.S. Serial No. 11/491,330 (Exhibit 18);
23. August 5, 2008 Final Office Action issued in connection with U.S. Serial No. 11/175,815 (Exhibit 19);
24. August 19, 2008 Office Action issued in connection with U.S. Serial No. 11/804,746 (Exhibit 20);
25. May 14, 2008 Office Action issued in connection with U.S. Serial No. 11/400,497 (Exhibit 21);
26. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued August 15, 2008 in connection with PCT International Application No. PCT/US08/05564 (Exhibit 22);
27. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued July 25, 2008 in connection with PCT International Application No. PCT/US06/28565 (Exhibit 23);
28. June 18, 2008 Communication including Partial European Search Report in connection with European Patent Application No. 07 01 4859.8 (Exhibit 24); and
29. August 21, 2008 Office Action issued in connection with U.S. Serial No. 09/904,356 (Exhibit 25).

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. 1.97(c)(2). Accordingly, applicants enclose herewith a check including the amount of \$180.00.


The Examiner is respectfully requested to make the listed items of record in the present application by initialing and returning a copy of the enclosed Substitute Form PTO 1449.


Applicants: Graham P. Allaway et al.
U.S. Serial No.: 09/888,938
Filed: June 25, 2001
Page 15

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed total fee of \$705.00, including \$525.00 for a three-month extension of time and a \$180.00 Information Disclosure Statement fee, is deemed necessary in connection with the filing of this Communication and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited on this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
	9/11/08
John P. White Reg. No. 28,678	Date


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400